To evaluate differences in factors associated with self-reported medication non-adherence to insulin and non-insulin medications in patients with uncontrolled type 2 diabetes.
Methods
In this secondary analysis of a randomized trial in patients with obesity and uncontrolled type 2 diabetes, multivariable logistic regression was used to evaluate associations between several clinical factors (measured with survey questionnaires at study baseline) and self-reported non-adherence to insulin and non-insulin medications.
Results
Among 263 patients, reported non-adherence was 62% (52% for insulin, 55% for non-insulin medications). Reported non-adherence to non-insulin medications was less likely in white versus non-white patients (odds ratio (OR) = 0.42; 95%CI: 0.22,0.80) and with each additional medication taken (OR = 0.75; 95%CI: 0.61,0.93). Non-adherence to non-insulin medications was more likely with each point increase in a measure of diabetes medication intensity (OR = 1.43; 95%CI: 1.01,2.03), the Problem Areas in Diabetes (PAID) score (OR = 1.06; 95%CI: 1.02,1.12), and in men versus women (OR = 3.03; 95%CI: 1.06,8.65). For insulin, reporting non-adherence was more likely (OR = 1.02; 95%CI: 1.00,1.04) with each point increase in the PAID.
Discussion
Despite similar overall rates of reported non-adherence to insulin and non-insulin medications, factors associated with reported non-adherence to each medication type differed. These findings may help tailor approaches to supporting adherence in patients using different types of diabetes medications.
RozenfeldYHuntJSPlauschinatC, et al.
Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care2008;
14: 71–75.
4.
LipskaKJYaoXHerrinJ, et al.
Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Dia Care2017;
40: 468–475.
5.
KrassISchiebackPDhippayomT.Adherence to diabetes medication: a systematic review. Diabet Med2015;
32: 725–737.
6.
AlexopoulosAS, et al.
Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. Chronic Illn2019. Epub ahead of print 25 October 2019. DOI:10.1177/1742395319884096
7.
McGovernATippuZHintonW, et al.
Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab2018;
20: 1040–1043.
StolpeSKroesMAWebbN, et al.
A systematic review of insulin adherence measures in patients with diabetes. J Manag Care Spec Pharm2016;
22: 1224–1246.
10.
CrowleyMJEdelmanDVoilsCI, et al.
Jump starting shared medical appointments for diabetes with weight management: rationale and design of a randomized controlled trial. Contemp Clin Trials2017;
58: 1–12.
11.
ZammittNNStreftarisGGibsonGJ, et al.
Modeling the consistency of hypoglycemic symptoms: high variability in diabetes. Diabetes Technol Ther2011;
13: 571–578.
12.
MayerSBJeffreysASOlsenMK, et al.
Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. Diabetes Obes Metab2014;
16: 90–93.
13.
PickardASDe LeonMCKohlmannT, et al.
Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care2007;
45: 259–263.
14.
SnoekFJPouwerFWelchGW, et al.
Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the problem areas in diabetes scale. Diabetes Care2000;
23: 1305–1309.
15.
KroenkeKSpitzerRLWilliamsJB.The patient health questionnaire-2: validity of a two-item depression screener. Med Care2003;
41: 1284–1292.
16.
VoilsCI, et al.
Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care2012;
50: 1013–1019.
17.
BlalockDVZulligLLBosworthHB, et al.
Self-reported medication nonadherence predicts cholesterol levels over time. J Psychosom Res2019;
118: 49–55.
18.
VoilsCIKingHAThorpeCT, et al.
Content validity and reliability of a self-report measure of medication nonadherence in hepatitis C treatment. Dig Dis Sci2019;
64: 2784–2797.
19.
DaviesMJGagliardinoJJGrayLJ, et al.
Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med2013;
30: 512–524.
20.
EgedeLEGebregziabherMHuntKJ, et al.
Regional, geographic, and ethnic differences in medication adherence among adults with type 2 diabetes. Ann Pharmacother2011;
45: 169–178.
21.
RatanawongsaNCrossonJCSchillingerD, et al.
Getting under the skin of clinical inertia in insulin initiation: the translating research into action for diabetes (TRIAD) insulin starts project. Diabetes Educ2012;
38: 94–100.
22.
PolonskyWHAndersonBJLohrerPA, et al.
Insulin omission in women with IDDM. Diabetes Care1994;
17: 1178–1185.
23.
GoldenSHBrownACauleyJA, et al.
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors – an endocrine society scientific statement. J Clin Endocrinol Metab2012;
97: E1579–E1639.
24.
AdamsASBanerjeeSKuCJ. Medication adherence and racial differences in diabetes in the USA: an update. Diabetes Manag 2015;
5: 79–87.
25.
DonnanPTMacDonaldTMMorrisAD.Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med2002;
19: 279–284.
26.
MelikianCWhiteTJVanderplasA, et al.
Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther2002;
24: 460–467.
27.
RousselRCharbonnelBBeharM, et al.
Persistence with insulin therapy in patients with type 2 diabetes in France: an insurance claims study. Diabetes Ther2016;
7: 537–549.
28.
BaserO, et al.
Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res2013;
5: 497–505.
29.
BashetiIAAl-QudahRAObeidatNM, et al.
Home medication management review in outpatients with chronic diseases in Jordan: a randomized control trial. Int J Clin Pharm2016;
38: 404–413.
30.
CampinsLSerra-PratMGózaloI, et al.
Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract2017;
34: 36–42.
31.
LoweCJRaynorDKPurvisJ, et al.
Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol2000;
50: 172–175.
32.
SturgessIKMcElnayJCHughesCM, et al.
Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci2003;
25: 218–226.
33.
VinksTHAMEgbertsTCGde LangeTM, et al.
Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging2009;
26: 123–133.
34.
ChewBHVosRCMetzendorfM-I, et al.
Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev2017;
9: Cd011469.
35.
AikensJE.Prospective associations between emotional distress and poor outcomes in type 2 diabetes. Diabetes Care2012;
35: 2472–2478.
36.
MesaMS.Health care disparities between men and women with type 2 diabetes. Prev Chronic Dis2018;
15: E46.
37.
CohenHWShmuklerCUllmanR, et al.
Measurements of medication adherence in diabetic patients with poorly controlled HbA(1c). Diabet Med2010;
27: 210–216.
